Results 91 to 100 of about 3,071,059 (368)

IP round-up: Recent decisions from the courts (February 2008) [PDF]

open access: yes, 2008
This Supreme Court decision was an appeal from the Court of Appeal decision in Stichting Lodestar v Austin, Nichols & Co. Inc.. The decision clarifies the approach that the High Court should take on an appeal against a decision of the Commissioner of ...
Kingsbury, Anna
core   +1 more source

Screening for lung cancer: A systematic review of overdiagnosis and its implications

open access: yesMolecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz   +12 more
wiley   +1 more source

Optimal condition determination for Ajwain (Carum capticum) standard germination test [PDF]

open access: yesعلوم و فناوری بذر ایران
Randomized factorial design was implemented in four replications to determine optimal methods of Ajwain (Carum capticum) standard seeds germination. Ajwain seeds were placed top and between paper and sand exposed to two potassium nitrate (two grams per ...
Ali Shayanfar   +4 more
doaj   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

open access: yesMolecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece   +18 more
wiley   +1 more source

UK electoral registration levels are already low by international standards, but new plans to change registration may make things even worse [PDF]

open access: yes, 2011
Alongside a suite of other constitutional reforms, the coalition government also plans to change electoral registration from household to individual registration. Toby S. James argues that this change will be expensive to implement and will actually lead
James, Toby
core  

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Time trends and patterns of primary liver cancer in Guangzhou from 2004 to 2015

open access: yesPrecision Radiation Oncology, 2017
Objective To analyze the epidemiological trends and patterns of primary liver cancer (PLC) in Guangzhou, China, between 2004 and 2015, and provide a basis for making control measures and strategies for prevention. Methods The data were extracted from the
Ke Li, Guozhen Lin, Yan Li, Huan Xu
doaj   +1 more source

Derringer desirability and kinetic plot LC-column comparison approach for MS-compatible lipopeptide analysis

open access: yesJournal of Pharmaceutical Analysis, 2014
Lipopeptides are currently re-emerging as an interesting subgroup in the peptide research field, having historical applications as antibacterial and antifungal agents and new potential applications as antiviral, antitumor, immune-modulating and cell ...
Matthias D’Hondt   +5 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy